Once-daily amoxicillin for pharyngitis

Area of Science:

• Infectious Diseases
• Pharmacology
• Pediatrics

Background:

• Group A β-hemolytic streptococcal pharyngitis (GABHS) can lead to rheumatic fever, a serious complication.
• Current treatment guidelines often involve multiple daily antibiotic doses, potentially impacting patient adherence.
• Improving compliance is crucial for effective GABHS treatment and secondary prevention of rheumatic fever.

Purpose of the Study:

• To evaluate the efficacy and compliance of a once-daily antibiotic regimen for GABHS.
• To assess the cost-effectiveness of once-daily amoxicillin compared to other GABHS treatments.
• To support the American Heart Association's recommendation for once-daily amoxicillin.

Main Methods:

• Review of existing literature and FDA-approved once-daily GABHS treatments.
• Comparative analysis of antibiotic costs and dosing frequencies.
• Assessment of amoxicillin's efficacy in once-daily regimens versus conventional dosing.

Main Results:

• Once-daily amoxicillin is a cost-effective option for GABHS treatment.
• Alternative once-daily antibiotics (azithromycin, cefadroxil, etc.) are available but more expensive.
• Once-daily amoxicillin demonstrates comparable efficacy to multiple daily dosing regimens.

Conclusions:

• Once-daily amoxicillin is an effective and affordable strategy for treating GABHS.
• This regimen enhances patient compliance and aids in rheumatic fever prevention.
• Amoxicillin's once-daily dosing presents a viable alternative to conventional penicillin treatments.